Ftse Mib
33.294,96
0,00%
DAX
19.146,17
0,76%
S&P 500
5.948,71
0,53%
NASDAQ
18.972,42
0,03%
Bitcoin
99.402,86
0,90%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Monopar Therapeutics Inc (MNPR) Monopar Therapeutics Inc (MNPR) Notizie

Monopar Therapeutics Inc

MNPR
19,71
0,71 (3,74%)
22 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/11/202414:02EDGAR2Form 8-K - Current report
08/11/202414:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202414:00GLOBEMonopar Therapeutics Reports Third Quarter 2024 Financial..
30/10/202421:05EDGAR2Form 8-K - Current report
30/10/202418:42GLOBEMonopar Therapeutics Inc. Announces Closing of $19.2 Million..
29/10/202421:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/10/202402:15GLOBEMonopar Therapeutics Inc. Announces Pricing of $19.2 Million..
28/10/202421:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/10/202421:00GLOBEMonopar Therapeutics Inc. Announces Proposed Public Offering..
24/10/202413:00EDGAR2Form 8-K - Current report
24/10/202413:00GLOBEMonopar Announces Agreement with Alexion, AstraZeneca Rare..
22/10/202414:00EDGAR2Form 8-K - Current report
22/10/202414:00GLOBEMonopar Presents Encouraging Human Clinical Dosimetry Data..
15/10/202414:00EDGAR2Form 8-K - Current report
15/10/202414:00GLOBEMonopar Expands Radiopharma Intellectual Property Portfolio..
07/10/202414:00EDGAR2Form 8-K - Current report
07/10/202414:00GLOBEMonopar Initiates Clinical Trial of Novel uPAR-Targeted..
03/10/202401:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202401:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202414:00EDGAR2Form 8-K - Current report
12/9/202414:00GLOBEMonopar Announces Positive Early Human Clinical Data..
04/9/202414:00GLOBEMonopar to Participate in the H.C. Wainwright 26th Annual..
27/8/202422:07EDGAR2Form 8-K - Current report
27/8/202422:05GLOBEMonopar Regains Compliance with Nasdaq Minimum Bid Price..
21/8/202414:00EDGAR2Form 8-K - Current report
21/8/202414:00GLOBEMonopar Receives Clearance to Proceed with Phase 1..
14/8/202414:00EDGAR2Form 8-K - Current report
14/8/202414:00GLOBEMonopar Announces Initial Data for First Patient Dosed in..
09/8/202414:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202414:01EDGAR2Form 8-K - Current report
09/8/202414:00GLOBEMonopar Therapeutics Reports Second Quarter 2024 Financial..
22/7/202413:01EDGAR2Form ARS - Annual Report to Security Holders
22/7/202413:00EDGAR2Form DEF 14A - Other definitive proxy statements
11/7/202422:30EDGAR2Form PRE 14A - Other preliminary proxy statements
09/7/202422:01EDGAR2Form 8-K - Current report
09/7/202413:00GLOBEMonopar Announces First Patient Enrolled in First-in-Human..
25/6/202414:00GLOBEMonopar Announces MNPR-101-RIT Abstract Accepted as a..
18/6/202400:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202413:30EDGAR2Form 8-K - Current report
11/6/202413:30GLOBEMonopar and NorthStar Amend & Extend Collaboration
10/6/202414:00EDGAR2Form 8-K - Current report
10/6/202414:00GLOBEMonopar Presents Data Showcasing the Appeal of uPAR as a..
06/6/202400:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/5/202422:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/5/202400:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202414:00EDGAR2Form 8-K - Current report
24/5/202414:00GLOBEMonopar Announces CFO Succession
09/5/202413:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202413:00EDGAR2Form 8-K - Current report
Apertura: 19,03 Min: 19,03 Max: 20,13
Chiusura: 19,00

La tua Cronologia

NASDAQ
MNPR
Monopar Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network